UNSPSC 51292204: Itopride

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81BMQ80QRL. European Medicines Agency schedules Itopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08352MIG. Itopride generally arises in the molecular formula C20H26N2O4.

UNSPSC 51292204 Itopride is a Commodity code representing pharmaceutical and over-the-counter (OTC) products being procured by state and local health agencies, primarily through competitive sealed bidding and cooperative purchasing frameworks. State and local governments buy naloxone, generic pharmaceuticals, OTC products, and drug deactivation systems under this code, sourced through authorized wholesalers or direct manufacturer relationships and distributed to county health departments, state HHS commissions, and multistate purchasing cooperatives serving participating jurisdictions. Recent solicitations show county health departments and state health agencies issuing IFBs and RFPs for pharmaceutical procurement, with responses structured around fixed pricing, competitive bidding on National Drug Codes (NDCs), and compliance with Drug Supply Chain Security Act (DSCSA) and current Good Manufacturing Practices (cGMP) requirements. Vendors must maintain relationships with authorized drug wholesalers, demonstrate EDI capability, carry specified insurance coverages including commercial general liability and professional liability, and comply with E-Verify and drug-free workplace certification standards.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026; pricing is weighted at 75 percent of evaluation, with compliance and administrative requirements comprising the remainder. The Texas Health and Human Services Commission posted an exploratory RFI in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Contracts typically run two years with renewal options, and awards are made on fixed-fee or competitive pricing bases with administrative fees ranging from 3 percent to contract-specific terms.